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Association, and the Swiss Acad­
emy of Medical Sciences, was 
mandated to prepare a review of 
mammography screening. The two 
of us, a medical ethicist and a 
clinical epidemiologist, were mem­
bers of the expert panel that ap­
praised the evidence and its impli­
cations. The other members were 
a clinical pharmacologist, an onco­
logic surgeon, a nurse scientist, a 
lawyer, and a health economist. 
As we embarked on the project, we 
were aware of the controversies 
that have surrounded mammog­
raphy screening for the past 10 to 
15 years. When we reviewed the 
available evidence and contem­
plated its implications in detail, 
however, we became increasingly 
concerned.
First, we noticed that the ongo­
ing debate was based on a series of 
reanalyses of the same, predomi­
nantly outdated trials. The first 
trial started more than 50 years 
ago in New York City and the last 
trial in 1991 in the United King­
dom.1 None of these trials were 
initiated in the era of modern 
breast­cancer treatment, which has 
dramatically improved the progno­
sis of women with breast cancer. 
Could the modest benefit of mam­
mography screening in terms of 
breast­cancer mortality that was 
shown in trials initiated between 
1963 and 1991 still be detected in 
a trial conducted today?
Second, we were struck by how 
nonobvious it was that the bene­
fits of mammography screening 
outweighed the harms. The rela­
tive risk reduction of approximate­
ly 20% in breast­cancer mortality 
associated with mammography 
that is currently described by most 
expert panels2 came at the price 
of a considerable diagnostic cas­
cade, with repeat mammography, 
subsequent biopsies, and overdiag­
nosis of breast cancers — can­
cers that would never have become 
clinically apparent. The recently 
published extended follow­up of 
the Canadian National Breast 
Screening Study is likely to pro­
vide reliable estimates of the extent 
of overdiagnosis. After 25 years of 
follow­up, it found that 106 of 484 
screen­detected cancers (21.9%) 
were overdiagnosed.3 This means 
that 106 of the 44,925 healthy 
women in the screening group 
were diagnosed with and treated 
for breast cancer unnecessarily, 
which resulted in needless sur­
gical interventions, radiotherapy, 
chemotherapy, or some combina­
tion of these therapies. In addition, 
a Cochrane review of 10 trials in­
volving more than 600,000 women 
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In January 2013, the Swiss Medical Board, an in­dependent health technology assessment initiative 
under the auspices of the Conference of Health  
Ministers of the Swiss Cantons, the Swiss Medical 
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showed there was no evidence 
suggesting an effect of mammog­
raphy screening on overall mortal­
ity.1 In the best case, the small 
reduction in breast­cancer deaths 
was attenuated by deaths from 
other causes. In the worst case, 
the reduction was canceled out by 
deaths caused by coexisting condi­
tions or by the harms of screen­
ing and associated overtreatment. 
Did the available evidence, taken 
together, indicate that mammog­
raphy screening indeed benefits 
women?
Third, we were disconcerted by 
the pronounced discrepancy be­
tween women’s perceptions of the 
benefits of mammography screen­
ing and the benefits to be expect­
ed in reality. The figure shows 
the numbers of 50­year­old women 
in the United States expected to 
be alive, to die from breast can­
cer, or to die from other causes if 
they are invited to undergo regular 
mammography every 2 years over 
a 10­year period, as compared 
with women who do not undergo 
mammography. The numbers in 
Panel A are derived from a survey 
about U.S. women’s perceptions,4 
in which 717 of 1003 women 
(71.5%) said they believed that 
mammography reduced the risk 
of breast­cancer deaths by at least 
half, and 723 women (72.1%) 
thought that at least 80 deaths 
would be prevented per 1000 
women who were invited for 
screening. The numbers in Panel B 
reflect the most likely scenarios 
according to available trials1-3: 
a relative risk reduction of 20% 
and prevention of 1 breast­cancer 
death. The data for Switzerland, 
reported in the same study, show 
similarly overly optimistic expec­
tations. How can women make 
an informed decision if they over­
estimate the benefit of mammog­
raphy so grossly?
The Swiss Medical Board’s re­
port was made public on February 
2, 2014 (www.medical­board.ch). 
It acknowledged that systematic 
mammography screening might 
prevent about one death attri­
buted to breast cancer for every 
1000 women screened, even 
though there was no evidence to 
suggest that overall mortality was 
affected. At the same time, it em­
phasized the harm — in particu­
lar, false positive test results and 
the risk of overdiagnosis. For every 
breast­cancer death prevented in 
U.S. women over a 10­year course 
of annual screening beginning at 
50 years of age, 490 to 670 women 
are likely to have a false positive 
mammogram with repeat exami­
nation; 70 to 100, an unnecessary 
biopsy; and 3 to 14, an overdiag­
nosed breast cancer that would 
never have become clinically ap­
parent.5 The board therefore rec­
ommended that no new systematic 
mammography screening pro­
grams be introduced and that a 
time limit be placed on existing 
programs. In addition, it stipulat­
ed that the quality of all forms of 
mammography screening should 
be evaluated and that clear and 
balanced information should be 
provided to women regarding the 
benefits and harms of screening.
The report caused an uproar 
Abolishing Mammography Screening Programs?
A Women’s Perception of the Effect of Mammography
B Real Effect of Mammography
With screening Without screening
With screening Without screening
881 Women alive 801 Women alive
80 Women
die from
breast 
cancer
39 Women
die from
other causes 
160 Women
die from
breast
cancer 
5 Women
die from
breast
cancer 
39 Women
die from
other causes 
39 or 40 
Women
die from
other causes 
39 Women
die from
other causes 
956 or 957 Women alive 956 Women alive
4 Women
die from
breast
cancer 
U.S. Women’s Perceptions of the Effects of Mammography Screening on Breast-Cancer Mortality 
as Compared with the Actual Effects.
Panel A shows the views of 50-year-old women in the United States regarding the effect of mammog-
raphy every 2 years on the 10-year risk of death from breast cancer (at left), as compared with no 
screening (at right). The areas of the squares are proportional to the numbers of women per 1000 
who would be alive (blue), die from breast cancer (orange), or die from other causes (yellow). 
The numbers were calculated from women’s perceived relative and absolute risk reductions for 
breast-cancer deaths (Domenighetti et al.4) and U.S. mortality statistics for 2008 from the Centers 
for Disease Control and Prevention. Panel B shows the actual effect of mammography screening 
on breast-cancer deaths, with numbers calculated from breast-cancer mortality data for 2008 from 
the National Cancer Institute and U.S. mortality statistics for 2008, assuming a relative risk reduction 
of 20% for breast-cancer mortality in women invited to undergo screening (Independent U.K. Panel2).
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and was emphatically rejected by 
a number of Swiss cancer experts 
and organizations, some of which 
called the conclusions “unethi­
cal.” One of the main arguments 
used against it was that it contra­
dicted the global consensus of 
leading experts in the field — a 
criticism that made us appreciate 
our unprejudiced perspective re­
sulting from our lack of expo­
sure to past consensus­building 
efforts by specialists in breast­
cancer screening. Another argu­
ment was that the report unset­
tled women, but we wonder how 
to avoid unsettling women, given 
the available evidence.
The Swiss Medical Board is 
nongovernmental, and its recom­
mendations are not legally bind­
ing. Therefore, it is unclear wheth­
er the report will have any effect 
on the policies in our country. 
Although Switzerland is a small 
country, there are notable differ­
ences among re­
gions, with the 
French­ and Italian­
speaking cantons 
being much more 
in favor of screening programs 
than the German­speaking can­
tons — a finding suggesting that 
cultural factors need to be taken 
into account. Eleven of the 26 
Swiss cantons have systematic 
mammography screening pro­
grams for women 50 years of 
age or older; two of these pro­
grams were introduced only last 
year. One German­speaking can­
ton, Uri, is reconsidering its de­
cision to start a mammography 
screening program in light of the 
board’s recommendations. Partici­
pation in existing programs 
ranges from 30 to 60% — varia­
tion that can be partially ex­
plained by the coexistence of op­
portunistic screening offered by 
physicians in private practice. At 
least three quarters of all Swiss 
women 50 years of age or older 
have had a mammogram at least 
once in their life. Health insurers 
are required to cover mammog­
raphy as part of systematic screen­
ing programs or within the frame­
work of diagnostic workups of 
potential breast disease.
It is easy to promote mam­
mography screening if the major­
ity of women believe that it pre­
vents or reduces the risk of 
getting breast cancer and saves 
many lives through early detec­
tion of aggressive tumors.4 We 
would be in favor of mammogra­
phy screening if these beliefs 
were valid. Unfortunately, they are 
not, and we believe that women 
need to be told so. From an ethi­
cal perspective, a public health 
program that does not clearly 
produce more benefits than harms 
is hard to justify. Providing clear, 
unbiased information, promoting 
appropriate care, and preventing 
overdiagnosis and overtreatment 
would be a better choice.
The views expressed in this article are 
those of the authors and do not necessarily 
ref lect those of all members of the expert 
panel of the Swiss Medical Board.
Disclosure forms provided by the authors 
are available with the full text of this article 
at NEJM.org.
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The Legality of Delaying Key Elements of the ACA
Nicholas Bagley, J.D.
Under the Affordable Care Act (ACA), the employer mandate 
— the requirement that most em­
ployers offer health insurance to 
their workers or pay a tax pen­
alty — was scheduled to go into 
effect on January 1, 2014. Last 
summer, however, the Obama 
administration announced that it 
was delaying the mandate for a 
year. The administration has 
now extended the delay for mid­
size firms until 2016.
The latest delay has spurred 
another round of accusations 
from critics of health care reform 
that the Obama administration 
has acted unlawfully in imple­
menting the ACA. Similar accu­
sations followed the announce­
ment of a 1­year delay for some 
insurers of the ACA caps on out­
of­pocket costs, as well as the de­
cision to allow people to keep 
An audio interview 
with Dr. Mette Kalager 
about the Swiss Medical 
Board recommendation 
is available at NEJM.org 
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